General Information
Akcea Ionis TRG ISIS 678354-CS2
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients with Hypertriglyceridemia and Established Cardiovascular Disease (CVD)
| Protocol | ISIS 678354-CS2 |
|---|---|
| Identifier | APOCIII_LRx |
| UID | 3404bbb5-1eab-49bc-9e87-806e39638935 |
| Status | Done - Archived |
| Phase | 2 |
| Category | / Adult |
| Launch Year | 2018 |
| NCT Number | - |
| Created | 2018-08-03 12:59 |
| Last Updated | 2018-08-03 12:59 |
Description
No description provided.
Comment
CRI
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2019-04-24 | No |
| Enrollment Open | 2018-10-11 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2018-10-11 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2019-08-07 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | - | No | |
| Coordinator | Gallardo, Michael | MGallardo | No |
| Regulatory | Ramirez, Claudia | CRamirez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Akcea Ionis Pharmaceuticals |
|---|---|
| Division | Akcea Ionis Pharmaceuticals |
| Team | Akcea Ionis Pharmaceuticals |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | Worldwide Clinical Trials, Inc. (NC) |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
